vs
Side-by-side financial comparison of Penumbra Inc (PEN) and SPX Technologies, Inc. (SPXC). Click either name above to swap in a different company.
SPX Technologies, Inc. is the larger business by last-quarter revenue ($566.8M vs $385.4M, roughly 1.5× Penumbra Inc). Penumbra Inc runs the higher net margin — 12.3% vs 10.6%, a 1.7% gap on every dollar of revenue. On growth, Penumbra Inc posted the faster year-over-year revenue change (22.1% vs 22.0%). Penumbra Inc produced more free cash flow last quarter ($68.0M vs $11.3M). Over the past eight quarters, Penumbra Inc's revenue compounded faster (17.6% CAGR vs 6.3%).
Penumbra, Inc. is an American medical device company headquartered in Alameda, California. The company was founded by Arani Bose and Adam Elsesser in 2004. It manufactures devices for interventional therapies to treat vascular conditions such as stroke and aneurysm.
SPX Technologies, Inc. is an American manufacturing company, headquartered in Charlotte, North Carolina. The company operates within four markets: heating, ventilation, and air conditioning (HVAC), detection and measurement, power transmission and generation, and engineered solutions. Examples of SPX’s products include cooling towers and boilers, underground pipe and cable locators, power transformers, and heat exchangers. Brands include Waukesha, Dielectric, Genfare, Fahrenheat, Radiodetecti...
PEN vs SPXC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $385.4M | $566.8M |
| Net Profit | $47.3M | $59.9M |
| Gross Margin | 68.0% | — |
| Operating Margin | 15.4% | 15.5% |
| Net Margin | 12.3% | 10.6% |
| Revenue YoY | 22.1% | 22.0% |
| Net Profit YoY | 40.6% | 17.0% |
| EPS (diluted) | $1.20 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $566.8M | ||
| Q4 25 | $385.4M | $637.3M | ||
| Q3 25 | $354.7M | $592.8M | ||
| Q2 25 | $339.5M | $552.4M | ||
| Q1 25 | $324.1M | $482.6M | ||
| Q4 24 | $315.5M | $533.7M | ||
| Q3 24 | $301.0M | $483.7M | ||
| Q2 24 | $299.4M | $501.3M |
| Q1 26 | — | $59.9M | ||
| Q4 25 | $47.3M | $77.9M | ||
| Q3 25 | $45.9M | $62.7M | ||
| Q2 25 | $45.3M | $52.2M | ||
| Q1 25 | $39.2M | $51.2M | ||
| Q4 24 | $33.7M | $57.1M | ||
| Q3 24 | $29.5M | $50.2M | ||
| Q2 24 | $-60.2M | $44.2M |
| Q1 26 | — | — | ||
| Q4 25 | 68.0% | 39.8% | ||
| Q3 25 | 67.8% | 40.4% | ||
| Q2 25 | 66.0% | 41.4% | ||
| Q1 25 | 66.6% | 40.6% | ||
| Q4 24 | 66.8% | 40.9% | ||
| Q3 24 | 66.5% | 40.9% | ||
| Q2 24 | 54.4% | 40.1% |
| Q1 26 | — | 15.5% | ||
| Q4 25 | 15.4% | 15.7% | ||
| Q3 25 | 13.8% | 16.4% | ||
| Q2 25 | 12.0% | 15.7% | ||
| Q1 25 | 12.4% | 13.8% | ||
| Q4 24 | 13.6% | 16.9% | ||
| Q3 24 | 11.7% | 16.3% | ||
| Q2 24 | -27.0% | 14.9% |
| Q1 26 | — | 10.6% | ||
| Q4 25 | 12.3% | 12.2% | ||
| Q3 25 | 12.9% | 10.6% | ||
| Q2 25 | 13.3% | 9.4% | ||
| Q1 25 | 12.1% | 10.6% | ||
| Q4 24 | 10.7% | 10.7% | ||
| Q3 24 | 9.8% | 10.4% | ||
| Q2 24 | -20.1% | 8.8% |
| Q1 26 | — | — | ||
| Q4 25 | $1.20 | $1.56 | ||
| Q3 25 | $1.17 | $1.28 | ||
| Q2 25 | $1.15 | $1.10 | ||
| Q1 25 | $1.00 | $1.09 | ||
| Q4 24 | $0.88 | $1.21 | ||
| Q3 24 | $0.75 | $1.06 | ||
| Q2 24 | $-1.55 | $0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $186.9M | $156.5M |
| Total DebtLower is stronger | — | $667.3M |
| Stockholders' EquityBook value | $1.4B | $2.3B |
| Total Assets | $1.8B | $3.9B |
| Debt / EquityLower = less leverage | — | 0.29× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $156.5M | ||
| Q4 25 | $186.9M | $364.0M | ||
| Q3 25 | $321.0M | $229.4M | ||
| Q2 25 | $421.8M | $132.8M | ||
| Q1 25 | $376.1M | $177.8M | ||
| Q4 24 | $324.4M | $156.9M | ||
| Q3 24 | $280.5M | $124.8M | ||
| Q2 24 | $288.3M | $128.1M |
| Q1 26 | — | $667.3M | ||
| Q4 25 | — | $496.7M | ||
| Q3 25 | — | $499.8M | ||
| Q2 25 | — | $950.3M | ||
| Q1 25 | — | $872.0M | ||
| Q4 24 | — | $577.0M | ||
| Q3 24 | — | $665.2M | ||
| Q2 24 | — | $509.9M |
| Q1 26 | — | $2.3B | ||
| Q4 25 | $1.4B | $2.2B | ||
| Q3 25 | $1.4B | $2.1B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.2B | $1.4B | ||
| Q4 24 | $1.2B | $1.4B | ||
| Q3 24 | $1.1B | $1.4B | ||
| Q2 24 | $1.2B | $1.3B |
| Q1 26 | — | $3.9B | ||
| Q4 25 | $1.8B | $3.6B | ||
| Q3 25 | $1.7B | $3.4B | ||
| Q2 25 | $1.7B | $3.3B | ||
| Q1 25 | $1.6B | $3.1B | ||
| Q4 24 | $1.5B | $2.7B | ||
| Q3 24 | $1.5B | $2.8B | ||
| Q2 24 | $1.5B | $2.8B |
| Q1 26 | — | 0.29× | ||
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.62× | ||
| Q1 25 | — | 0.60× | ||
| Q4 24 | — | 0.42× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 0.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $86.5M | — |
| Free Cash FlowOCF − Capex | $68.0M | $11.3M |
| FCF MarginFCF / Revenue | 17.7% | 2.0% |
| Capex IntensityCapex / Revenue | 4.8% | 3.3% |
| Cash ConversionOCF / Net Profit | 1.83× | — |
| TTM Free Cash FlowTrailing 4 quarters | $174.9M | $268.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $86.5M | $195.2M | ||
| Q3 25 | $58.3M | $106.5M | ||
| Q2 25 | $44.9M | $42.5M | ||
| Q1 25 | $49.0M | $-10.9M | ||
| Q4 24 | $51.1M | $166.5M | ||
| Q3 24 | $56.5M | $51.4M | ||
| Q2 24 | $22.6M | $57.5M |
| Q1 26 | — | $11.3M | ||
| Q4 25 | $68.0M | $126.7M | ||
| Q3 25 | $42.0M | $96.1M | ||
| Q2 25 | $29.4M | $34.8M | ||
| Q1 25 | $35.5M | $-16.4M | ||
| Q4 24 | $45.7M | $156.7M | ||
| Q3 24 | $51.0M | $43.5M | ||
| Q2 24 | $18.1M | $47.1M |
| Q1 26 | — | 2.0% | ||
| Q4 25 | 17.7% | 19.9% | ||
| Q3 25 | 11.8% | 16.2% | ||
| Q2 25 | 8.7% | 6.3% | ||
| Q1 25 | 11.0% | -3.4% | ||
| Q4 24 | 14.5% | 29.4% | ||
| Q3 24 | 16.9% | 9.0% | ||
| Q2 24 | 6.0% | 9.4% |
| Q1 26 | — | 3.3% | ||
| Q4 25 | 4.8% | 10.7% | ||
| Q3 25 | 4.6% | 1.8% | ||
| Q2 25 | 4.6% | 1.4% | ||
| Q1 25 | 4.2% | 1.1% | ||
| Q4 24 | 1.7% | 1.8% | ||
| Q3 24 | 1.8% | 1.6% | ||
| Q2 24 | 1.5% | 2.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.83× | 2.51× | ||
| Q3 25 | 1.27× | 1.70× | ||
| Q2 25 | 0.99× | 0.81× | ||
| Q1 25 | 1.25× | -0.21× | ||
| Q4 24 | 1.52× | 2.92× | ||
| Q3 24 | 1.91× | 1.02× | ||
| Q2 24 | — | 1.30× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PEN
| Thrombectomy | $254.7M | 66% |
| Other | $130.7M | 34% |
SPXC
Segment breakdown not available.
